Search

Astellas Pharma Inc

Closed

1,528 2.28

Overview

Share price change

24h

Current

Min

1528

Max

1532

Key metrics

By Trading Economics

Income

16B

15B

Sales

-49B

373B

P/E

Sector Avg

80.468

EPS

4.33

Dividend yield

2.792

Profit margin

3.44

EBITDA

31B

66B

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.79%

Next Earnings

30 lip 2024

Market Stats

By TradingEconomics

Market Cap

-100B

2.7T

Previous open

1525.72

Previous close

1528

News Sentiment

By Acuity

24%

76%

Astellas Pharma Inc Chart

Related News

1 maj 2024, 16:54 UTC

Major Market Movers

Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences

7 sie 2023, 14:26 UTC

Major Market Movers

Poseida Therapeutics Shares Leap on Astellas Investments

28 sie 2023, 05:18 UTC

Acquisitions, Mergers, Takeovers

Novartis: Mycamine Is Antifungal Treatment

28 sie 2023, 05:16 UTC

Acquisitions, Mergers, Takeovers

Novartis: Sandoz Completes Acquisition of Mycamine Brand From Astellas

Astellas Pharma Inc Forecast

Sentiment

By Acuity

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Astellas Pharma Inc

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.